EDK
Editome Disease Knowledgebase
Lung Cancer
| Disease name | Lung Cancer |
|---|---|
| Classfication | Cancer |
| Related Enzyme(s) | |
| EFO | EFO:0001071 |
| DOID | 299 |
| OMIM | |
| NCI | |
| Definition | A carcinoma that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue. |
| Gene symbol | Species | Enzyme | Editing site(s) | Editing Type | PMID | RADAR | REDIportal | Description |
|---|---|---|---|---|---|---|---|---|
| BLCAP | Human | ADAR1;ADAR2 | 12 | A-to-I | BLCAP-editing level is Decrease in bladder cancer, astrocytomas, colorectal cancer. | |||
| NEIL1 | Human | ADAR1 | 1 | A-to-I | ADAR1 gene-amplified lung cancer cell lines show a higher frequency of A-to-I editing in NEIL1 relative to the ADAR1 normal copy number cells. | |||
| FAK | Human | ADAR1 | 1 | A-to-I | ADAR posttranscriptionally increased FAK protein abundance by binding to the FAK transcript and edit- ing a specific intronic site that resulted in the increased stabilization of FAK mRNA. Pharmacological inhibition of FAK blocked ADAR-induced invasiveness of LUAD cells, suggesting a potential therapeutic application for LUAD that has a high abundance of ADAR. |
| Gene symbol | Disease | Enzyme | Editing Sites | Editing Type | miRBase | PMID | Description |
|---|---|---|---|---|---|---|---|
| hsa-miR-381 | ADAR2 | 2 | A-to-I | MI0000789 | The A-to-I editing on the proposed targets contributed to the phenotype of lung cancer cells: we found that the overexpression of the edited miR-381 transcripts significantly enhances the growth of tumor cells in comparison with the transfection of the unedited transcripts. |
| Enzyme | Full Name | Location | Ensembl | Targets | Related Diseases | Aliases |
|---|---|---|---|---|---|---|
| ADAR1 | Adenosine deaminase, RNA specific | Chr1:154582057..154631560 |
|
|